Business Wire | Nov 5, 2020 08:00AM EST

Seagen Announces Multiple ADCETRIS(r) (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting

Nov. 05, 2020

BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 05, 2020--Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS(r) (brentuximab vedotin) data presentations at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020. Data presentations will include five-year updates from the phase 3 ECHELON-1 and ECHELON-2 clinical trials evaluating ADCETRIS plus a chemotherapy combination regimen in frontline advanced stage Hodgkin lymphoma (HL) or frontline peripheral T-cell lymphoma (PTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is being evaluated globally in more than 70 corporate- and investigator-sponsored clinical trials across multiple settings in lymphoma and other indications.

"At this year's ASH meeting, ADCETRIS will be featured in 18 data presentations, including five-year analyses from the ECHELON-1 and ECHELON-2 phase 3 frontline trials," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Reaching five-years without disease recurrence represents a significant clinical milestone for patients, as they may be considered disease-free at this time point. The five-year data presentations from our phase 3 ECHELON-1 and ECHELON-2 trials demonstrate ADCETRIS plus chemotherapy resulted in superior clinical activity and durable benefit when compared to outcomes with a standard chemotherapy regimen. We will also present additional analyses from trials evaluating ADCETRIS in combination with other therapies, with the goal of identifying potential new treatment strategies that improve outcomes for patients."

Details of Seagen Presentations at ASH:

Abstract PresentationAbstract Title # Presenter Type / Date

Company-Sponsored Trials

Frontline Brentuximab Vedotin as OralMonotherapy or in Combination for Older #471 presentation / C. YasenchakHodgkin Lymphoma Patients Sunday, Dec. 6 at 2:15 p.m. PT

Brentuximab Vedotin with Chemotherapy Posterfor Patients with Previously Untreated, presentation /Stage III/IV Classical Hodgkin #2973 Monday, Dec. 7, D. Strauslymphoma: 5-year Update of the 7:00 a.m. - 3:30ECHELON-1 Study p.m. PT

The ECHELON-2 Trial: 5-Year Results ofa Randomized, Double-Blind, Phase 3 PosterStudy of Brentuximab Vedotin and CHP presentation /(A+CHP) Versus CHOP in Frontline #1150 Saturday, Dec. S. HorwitzTreatment of Patients with 5, 7:00 a.m. -CD30-positive Peripheral T-cell 3:30 p.m. PTLymphoma

PosterEconomic Assessment of Diagnostic presentation /Revision in Peripheral T-cell Lymphoma #1606 Saturday, Dec. N. Liu 5, 7:00 a.m. - 3:30 p.m. PT

Nivolumab Combined with Brentuximab PosterVedotin for Relapsed/Refractory presentation /Mediastinal Gray Zone Lymphoma: Primary #2045 Sunday, Dec. 6, A. SantoroEfficacy and Safety Analysis of the 7:00 a.m. - 3:30Phase 2 CheckMate 436 Study p.m. PT

Real-World Characteristics of Patients Posterwith Classical Hodgkin Lymphoma presentation /Receiving Frontline Brentuximab Vedotin #2499 Sunday, Dec. 6, T. Phillipswith Chemotherapy: A Retrospective 7:00 a.m. - 3:30Analysis with Propensity Score Matching p.m. PT

Real-World Adherence to NationalComprehensive Cancer Network (NCCN) PosterGuidelines Regarding the Usage of PET/ presentation /CT and Reported Deauville Scores in #2033 Sunday, Dec. 6, C. YasenchakAdvanced Stage Classical Hodgkin 7:00 a.m. - 3:30Lymphoma: A Community Oncology Practice p.m. PTPerspective

SGN-CD30C, an Investigational PosterCD30-Directed Camptothecin presentation /Antibody-Drug Conjugate (ADC), Shows #2089 Sunday, Dec. 6, M. RyanStrong Anti Tumor Activity and Superior 7:00 a.m. - 3:30Tolerability in Preclinical Studies p.m. PT

Real-World Characteristics of Patients Posterwith Peripheral T-Cell Lymphoma presentation /Receiving Frontline Brentuximab Vedotin #3418 Monday, Dec. 7, J. Burkewith Chemotherapy: A Retrospective 7:00 a.m. - 3:30Analysis with Propensity Score Matching p.m. PT

Nodal Peripheral T-Cell Lymphoma with T PosterFollicular-Helper Phenotype: A presentation / AM.Different Entity? Results of the #2972 Monday, Dec. 7, Garcia-SanchoSpanish Retrospective Real-T Study 7:00 a.m. - 3:30 p.m. PT

Results from the International, PosterMulti-Center, Retrospective B-Holistic presentation /Study: Describing Treatment Pathways #2979 Monday, Dec. 7, B. Ferhanogluand Outcomes for Classical Hodgkin 7:00 a.m. - 3:30Lymphoma p.m. PT

Investigator-Sponsored Trials

Increased Tumor Specific Cytotoxic TCell Responses and Reversion to a OralFavorable Cytokine Profile after presentation /Treatment in Patients with Newly #595 Monday, Dec. 7 H. DaveDiagnosed High Risk Hodgkin Lymphoma at 9:15 a.m. PTTreated on Children's Oncology GroupTrial- AHOD1331

Addition of Brentuximab Vedotin to PosterGemcitabine in Relapsed or Refractory presentation /T-Cell Lymphoma: Results of a LYSA #1161 Saturday, Dec. O. TournilhacMulticenter, Phase II Study. "The TOTAL 5, 7:00 a.m. -Trial" 3:30 p.m. PT

A Pilot Study of Brentuximab Vedotin, PosterRituximab and Dose Attenuated CHP in presentation /Patients 75 Years and Older with #2102 Sunday, Dec. 6, P. ReaganDiffuse Large B-Cell Lymphoma 7:00 a.m. - 3:30 p.m. PT

Dose-Dense Brentuximab Vedotin Plus PosterIfosfamide, Carboplatin, and Etoposide presentation /(ICE) Is Highly Active for Second Line #2964 Monday, Dec. 7, R. LynchTreatment in Relapsed/Refractory 7:00 a.m. - 3:30Classical Hodgkin Lymphoma: Final p.m. PTResults of a Phase I/II Study

A Phase I Trial Assessing the PosterFeasibility of Romidepsin Combined with presentation /Brentuximab Vedotin for Patients #2970 Monday, Dec. 7, S. BartaRequiring Systemic Therapy for 7:00 a.m. - 3:30Cutaneous T-Cell Lymphoma p.m. PT

Trials-in-Progress

Trial-in-Progress: Brentuximab Vedotin Posterin Combination with Lenalidomide and presentation /Rituximab in Subjects with Relapsed or #2112 Sunday, Dec. 6, N. BartlettRefractory Diffuse Large B-Cell 7:00 a.m. - 3:30Lymphoma (DLBCL) p.m. PT

PosterA Phase 1 Study of Sea-CD70 in Myeloid presentation /Malignancies #2874 Monday, Dec. 7, A. Aribi 7:00 a.m. - 3:30 p.m. PT

Trial-in-Progress: Frontline PosterBrentuximab Vedotin and CHP (A+CHP) in presentation /Patients with Peripheral T-Cell #2976 Monday, Dec. 7, D. JagadeeshLymphoma with Less Than 10% CD30 7:00 a.m. - 3:30Expression p.m. PT

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of ADCETRIS plus chemotherapy combination regimens in frontline advanced stage Hodgkin lymphoma (HL) and frontline peripheral T-cell lymphoma (PTCL), and in other indications. Actual results or developments may differ materially from those projected or implied in these forward-looking statements due to factors such as unexpected adverse events, adverse regulatory actions, the degree of utilization and adoption of an approved treatment regimen by prescribing physicians, the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results and risks related to the duration and severity of the COVID-19 pandemic. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005329/en/

CONTACT: Media: Monique Greer (425) 527-4641 mgreer@seagen.com

CONTACT: Investors: Peggy Pinkston (425) 527-4160 ppinkston@seagen.com